Spero Therapeutics Income Statement (2016-2026)

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026	Jun2026
Revenue & cost
Revenue (Quarter)	0.71M	-12.44M	0.25M	0.90M	1.08M	16.77M	0.22M	2.72M	25.47M	-29.33M	0.14M	10.20M	0.07M	0.05M	0.01M			12.59M	0.26M
Operating items
Research & Development (Quarter)	14.44M	17.23M	16.97M	8.17M	7.36M	15.09M	8.98M	9.51M	16.39M	16.56M	17.33M	23.73M	26.86M	28.84M	13.61M	10.67M	8.60M	5.59M	2.91M	3.43M
Selling, General & Administrative (Quarter)	11.15M	13.02M	15.30M	8.05M	6.63M	6.50M	7.32M	6.10M	5.71M	6.43M	5.92M	5.53M	5.20M	7.06M	6.82M	5.88M	4.17M	4.30M	4.89M	6.49M
Restructuring Costs (Quarter)					-0.15M	-0.07M								0.88M	0.17M	0.08M
Other Operating Expenses (Quarter)				11.85M					5.31M								0.59M
Operating Expenses (Quarter)	25.59M	30.25M	32.28M	28.07M	13.84M	21.52M	16.30M	15.61M	27.41M	22.99M	23.25M	29.26M	32.06M	36.77M	20.61M	16.63M	13.36M	9.89M	7.80M	9.93M
Operating Income (Quarter)	-22.52M	-27.50M	-30.21M	-26.08M	-11.83M	21.71M	-14.23M	-12.89M	-1.93M	47.66M	-13.98M	-19.06M	-17.44M	-21.73M	-14.73M	-2.44M	-7.38M	29.26M	-7.54M	-9.93M
EBIT (Quarter)	-22.52M	-27.50M	-30.21M	-26.08M	-11.83M	21.71M	-14.23M	-12.89M	-1.93M	47.66M	-13.98M	-19.06M	-17.44M	-21.73M	-14.73M	-2.44M	-7.38M	29.26M	-7.54M	-9.93M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)			0.07M	0.01M		0.71M	0.96M	0.98M	0.95M	1.04M	1.33M	1.20M	1.18M	1.03M	0.86M	0.74M	0.53M	0.38M	0.34M	0.38M
Other Non Operating Income (Quarter)	-0.09M	0.52M	-0.01M	-0.01M	-0.02M	0.14M	-0.00M	-0.01M	-0.01M	0.00M	-0.01M	0.00M	-0.03M	0.10M	0.00M	0.00M	0.00M		-0.00M	-0.00M
Non Operating Income (Quarter)	0.00M	-1.74M	-2.62M	-2.60M	0.16M	0.85M	0.96M	0.98M	0.94M	1.05M	1.31M	1.20M	1.16M	1.13M	0.86M	0.74M	0.53M	0.38M	0.34M	0.37M
Net income details
EBT (Quarter)	-55.73M	-129.95M	-34.09M	-26.07M	-11.84M	-92.37M	-13.27M	-11.91M	-0.98M	-59.18M	-12.66M	-17.86M	-16.26M	-142.95M	-13.87M	-107.67M	-27.73M	29.58M	-7.38M	-9.61M
Tax Provisions (Quarter)									2.21M	0.39M			0.29M	-0.29M				0.26M
Profit After Tax (Quarter)	-22.52M	-29.24M	-32.83M	-28.68M	-11.68M	26.78M	-13.27M	-11.91M	-3.21M	51.21M	-12.70M	-17.90M	-17.10M	-20.89M	-13.90M	-1.70M	-7.40M	31.55M	-7.20M	-9.55M
Income from Non-Controlling Interests (Quarter)			-0.00M	0.01M
Income from Continuing Operations (Quarter)	-55.73M	-129.95M	-34.09M	-26.07M	-11.84M	-92.37M	-13.27M	-11.91M	-3.20M	-59.57M	-12.66M	-17.86M	-16.55M	-142.66M	-13.87M	-107.67M	-27.73M	29.32M	-7.38M	-9.61M
Consolidated Net Income (Quarter)	-55.73M	-129.95M	-34.09M	-26.07M	-11.84M	-92.37M	-13.27M	-11.91M	-3.20M	-59.57M	-12.66M	-17.86M	-16.55M	-142.66M	-13.87M	-107.67M	-27.73M	29.32M	-7.38M	-9.61M
Income towards Parent Company (Quarter)	-55.73M	-129.95M	-34.09M	-26.07M	-11.84M	-92.37M	-13.27M	-11.91M	-3.20M	-59.57M	-12.66M	-17.86M	-16.55M	-142.66M	-13.87M	-107.67M	-27.73M	29.32M	-7.38M	-9.61M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-55.73M	-129.95M	-34.09M	-26.07M	-11.84M	-92.37M	-13.27M	-11.91M	-3.20M	-59.57M	-12.66M	-17.86M	-16.55M	-142.66M	-13.87M	-107.67M	-27.73M	29.32M	-7.38M	-9.61M
Additional items
EPS (Basic) (Quarter)	-1.73	-4.21	-1.05	-0.79	-0.33	-2.46	-0.25	-0.23	-0.06	-1.13	-0.24	-0.33	-0.31	-2.64	-0.25	-1.92	-0.49	0.52	-0.13	-0.17
EPS (Diluted) (Quarter)	-1.73	-4.21	-1.05	-0.79	-0.33	-2.46	-0.25	-0.23	-0.06	-1.12	-0.24	-0.33	-0.31	-2.64	-0.25	-1.92	-0.49	0.50	-0.13	-0.17
Shares Outstanding (Quarter)	32.13M	30.90M	32.61M	32.98M	35.88M	37.59M	52.53M	52.57M	52.71M	52.70M	53.52M	53.96M	54.12M	54.04M	55.38M	56.03M	56.28M	56.02M	57.28M	57.28M
Shares Outstanding (Diluted) (Quarter)	32.13M	30.90M	32.61M	32.98M	35.88M	37.59M	52.53M	52.57M	52.71M	52.99M	53.52M	53.96M	54.12M	54.04M	55.38M	56.03M	56.28M	59.04M	57.28M	57.28M
EBITDA (Quarter)	-22.52M	-27.50M	-30.21M	-26.08M	-11.83M	21.71M	-14.23M	-12.89M	-1.93M	47.66M	-13.98M	-19.06M	-17.44M	-21.73M	-14.73M	-2.44M	-7.38M	29.26M	-7.54M
Shares Outstanding (Entity) (Quarter)	32.22M	32.39M	32.76M	35.07M	42.86M	37.59M	52.57M	52.57M	53.00M	53.00M	53.87M	54.01M	54.31M	54.59M	55.90M	56.19M	56.31M	56.41M	57.89M	58.23M
Interest Expenses (Quarter)	33.21M	102.44M	3.95M		0.00M	114.79M	0.00M	0.00M	0.00M	107.88M	0.01M	0.00M	0.00M	122.26M		105.97M	20.88M	0.06M	0.18M
Tax Rate (Quarter)									-224.47%	-0.65%			-1.78%	0.20%				0.88%

Research Tools

Datasets

Plans

Developers

Spero Therapeutics SPRO Income Statement (2016-2026)

Research Tools

Datasets

Plans

Developers

Spero Therapeutics SPRO Income Statement (2016-2026)

Create an account

Sign In

Reset Password